Ozempic, Wegovy, Rybelsus: Same Molecule, Different Drugs

Why one molecule became three drugs

Ozempic, Wegovy, and Rybelsus are not three different medicines in the pharmacological sense. Each contains the same active ingredient: semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk. What separates them is how the molecule is delivered, at what dose, and for which condition regulators have approved it.

The split reflects how drug development works in practice. Semaglutide was first studied and approved as a glucose-lowering agent for type 2 diabetes — that program produced the injectable Ozempic (approved in the United States in 2017) and later the oral tablet Rybelsus (2019). When trials showed that higher doses produced substantial weight loss, the manufacturer ran a separate development program for obesity, which led to Wegovy (2021) at a higher maximum dose than Ozempic.

Each indication required its own pivotal trials, its own dosing schedule, and its own regulatory submission. The result is three brands that share a molecule but not a label — and that distinction matters clinically, legally, and financially.

Injection versus tablet: the bioavailability problem

Semaglutide is a peptide, and peptides are fragile drugs. Taken by mouth in ordinary form, the molecule is degraded by stomach acid and digestive enzymes and crosses the gut lining poorly. The bioavailability of oral semaglutide is on the order of one percent — the vast majority of each tablet never reaches the bloodstream.

Rybelsus exists because of a workaround: the tablet co-formulates semaglutide with an absorption enhancer called SNAC (salcaprozate sodium). SNAC transiently raises the local pH in the stomach and protects the peptide long enough for a small fraction to be absorbed across the gastric mucosa. This is why the dosing instructions are unusually strict: the tablet must be taken on an empty stomach, with no more than half a glass of plain water (about 120 ml), and the patient must wait at least 30 minutes before eating, drinking, or taking other oral medications. Food, larger volumes of water, or other pills can cut the already-low absorption further.

The injectable products bypass this problem entirely. Subcutaneous injection delivers the molecule directly into tissue, where it is absorbed slowly and reaches effective concentrations reliably. That difference in delivery explains the seemingly paradoxical doses: a daily 14 mg tablet of Rybelsus delivers roughly comparable systemic exposure to a weekly 1 mg injection, because so little of the oral dose is absorbed.

What each approval actually covers

The label — not the molecule — defines what a drug is approved to treat, and the three labels diverge in important ways.

Ozempic is approved for glycemic control in type 2 diabetes, at weekly doses up to 2 mg. Based on the SUSTAIN-6 outcomes trial, which followed more than 3,000 high-risk patients, its label also includes reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

Wegovy is approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, at a weekly dose of 2.4 mg. This is the dose tested in the STEP program, including the landmark STEP 1 trial in which participants lost a mean of 14.9 percent of body weight over 68 weeks. Since March 2024, the Wegovy label also covers reduction of cardiovascular risk in adults with established cardiovascular disease and overweight or obesity — an expansion based on the SELECT trial, which showed a 20 percent reduction in major cardiovascular events in that population.

Rybelsus is approved for type 2 diabetes at 7 mg and 14 mg daily (after a 3 mg initiation month). Its cardiovascular data come from PIONEER 6, a dedicated outcomes trial that established cardiovascular safety and showed a nominally favorable trend, but which was not powered to demonstrate superiority — so, unlike its injectable siblings, the tablet carries no cardiovascular risk-reduction claim.

The off-label question

Because the molecule is identical, the practical question arises constantly: can Ozempic substitute for Wegovy, or Rybelsus for either? Legally, physicians in many countries may prescribe approved drugs off-label, and Ozempic has been widely prescribed for weight loss in people without diabetes — a practice that surged during the Wegovy shortages.

There are real caveats. The maximum Ozempic dose of 2 mg was not the dose tested in the obesity trials, and the obesity indication, with its specific dosing schedule and evidence base, belongs to Wegovy. Insurance coverage typically follows the label, which is why off-label use often fails at the pharmacy counter rather than in the consultation. And during shortage periods, off-label prescribing for weight loss diverted supply from patients with diabetes — one reason regulators and professional societies have urged prescribers to respect indications when supply is constrained.

The reverse question — using a diabetes product’s trial results to justify obesity treatment — is equally problematic. Dose, titration schedule, and studied population all differ. Any decision about which product, if any, suits an individual patient belongs with the prescribing physician, who can weigh indication, dose, comorbidities, and coverage together.

Cost and availability

All three brands are prescription-only and sit in the premium price segment, and none is available as a generic. What a patient actually pays depends heavily on country, insurance system, and indication: many payers cover semaglutide for type 2 diabetes but restrict or exclude coverage for weight management, which means the same molecule can be reimbursed under one brand and denied under another.

Availability has also been volatile. Demand for GLP-1 drugs repeatedly outstripped supply between 2022 and 2024, and regulators in the United States and Europe listed semaglutide products as being in shortage for extended periods. The shortage era spawned a market for compounded and counterfeit versions, prompting warnings from the FDA and the EMA; patients should obtain these medicines only through licensed pharmacies with a valid prescription. Given how quickly coverage policies and supply situations change, current cost and availability questions are best directed at the prescriber and the relevant insurer.

The bottom line

Same molecule, three drugs — and the differences are not marketing. Formulation determines how much of the dose ever reaches the blood, dose determines which effects were demonstrated in trials, and the label determines what regulators and insurers recognize. For glycemic control, Ozempic and Rybelsus are the approved options, with the choice between injection and tablet hinging on patient preference and the strict fasting routine the tablet demands. For chronic weight management, and for cardiovascular risk reduction in people with overweight or obesity and established heart disease, the evidence and the approval sit with Wegovy. Substituting one brand for another is a clinical and regulatory decision, not a cosmetic one — and it belongs in the hands of a physician.